ResearchMoz

Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth

Publisher Name » GBI Research
Published Date » 2012-12-14
No. Of Pages » 120

Rheumatology Therapeutics Market to 2018 Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Rheumatology Therapeutics Market to 2018 Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth. The report provides insights into the rheumatology therapeutics market forecasts until 2018 and examines global treatment usage patterns for various rheumatology disorders. It also looks at the geographical distribution of the rheumatology disorders therapeutics market across key geographies (the US, the top five countries of Europe, and Japan) and provides insights into the R&D pipeline and promising future blockbusters until 2018. The report also profiles major biopharmaceutical companies in the segment and analyzes M&A activity and licensing agreements.

The reports covers Rheumatoid Arthritis (RA), Osteoarthritis (OA), Systemic Lupus Erythematosus (SLE) and gout, as these are most prevalent forms of rheumatologic disease. The global rheumatology therapeutics market was estimated to be worth $17.1 billion in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 9.4% from 2005, and is forecast to grow at a CAGR of 4.8% to $23.8 billion by 2018.

Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) are the major drugs used in rheumatology therapeutics. Enbrel and Humira account for the majority of the market in the US. Enbrels patent is set to expire in October 2012, although this is not expected to have an immediate impact as biosimilars are not predicted to enter the market until 20162017. In March 2011, the Food and Drug Administration (FDA) approved Benlysta (belimumab) for the treatment of SLE and in July 2011, it was approved by the European Medicines Agency (EMA).

Scope

  • Data and analysis for the rheumatology therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain and Japan
  • Annualized market data for the rheumatology therapeutics market from 2005 to 2011, forecast to 2018
  • In-depth analysis of the acute and chronic rheumatology therapeutics markets
  • Market data for the geographical and therapeutic landscapes, including size, annual cost of therapy, revenues, and treatment usage patterns for the diseased population, treatment-seeking population, diagnosed population and prescription population
  • Key drivers and barriers that have had a significant impact on the market
  • Profiles of major biopharmaceutical markets in the rheumatology therapeutics segment, namely AstraZeneca, Eli Lilly, Pfizer, Janssen Biotech and UCB
  • Key M&A activity and licensing agreements from 2007 to April 2012 in the rheumatology therapeutics market

Reasons to buy

  • Build effective strategies for launching pipeline products by identifying potential geographies
  • Exploit in-licensing and out-licensing opportunities by identifying products to fill portfolio gaps
  • Develop key strategic initiatives by studying top competitors key strategies
  • Develop market-entry and market-expansion strategies by identifying the geographic markets poised for strong growth
Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9

2 Rheumatology Therapeutics Market to 2018 - Introduction 11
2.1 Introduction 11

3 Rheumatology Therapeutics Market to 2018 - Market Overview 12
3.1 Introduction 12
3.1.1 Revenue 14
3.1.2 Annual Cost of Treatment 16
3.1.3 Treatment Usage Pattern 18

4 Rheumatology Therapeutics Market to 2018 - Geographical Landscape Revenue Analysis by Geography 20
4.1 The US 20
4.1.1 Revenue 21
4.1.2 Annual Cost of Treatment 22
4.1.3 Treatment Usage Patterns 24
4.2 Top Five Countries of Europe 26
4.2.1 Introduction 26
4.2.2 Revenue 26
4.2.3 Annual Cost of Treatment 29
4.2.4 Treatment Usage Patterns 30
4.3 Japan 32
4.3.1 Revenue 32
4.3.2 Annual Cost of Treatment 34
4.3.3 Treatment Usage Patterns 36
4.4 Australia 38
4.4.1 Overview of Rheumatology Market 38
4.5 China 40
4.5.1 Revenue 40
4.6 India 42
4.6.1 Overview of Rheumatology Market 42

5 Rheumatology Therapeutics Market to 2018 - Therapeutic Landscape 44
5.1 Rheumatoid Arthritis Therapeutics Market 44
5.1.1 Introduction 44
5.1.2 Revenue 45
5.1.3 Revenue by Country 48
5.1.4 Annual Cost of Treatment 50
5.1.5 Treatment Usage Pattern 51
5.1.6 Treatment Flow Algorithm 53
5.1.7 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 53
5.2 Osteoarthritis Therapeutics Market 55
5.2.1 Introduction 55
5.2.2 Revenue 55
5.2.3 Revenue by Country 59
5.2.4 Annual Cost of Treatment 61
5.2.5 Treatment Flow Algorithm 62
5.2.6 Treatment Usage Pattern 63
5.2.7 Drivers and Barriers for the Osteoporosis Therapeutics Market 65
5.3 Gout Therapeutics Market 66
5.3.1 Introduction 66
5.3.2 Revenue 66
5.3.3 Revenue by Country 70
5.3.4 Annual Cost of Treatment 72
5.3.5 Treatment Usage Pattern 73
5.3.6 Treatment Flow Algorithm 75
5.3.7 Drivers and Barriers for the Gout Therapeutics Market 75
5.4 Systemic Lupus Erythematosus Therapeutics Market 77
5.4.1 Introduction 77
5.4.2 Revenue 78
5.4.3 Annual Cost of Treatment 83
5.4.4 Treatment Usage Pattern 85
5.4.5 Treatment Flow Algorithm 87
5.4.6 Drivers and Barriers for Systemic Lupus Erythematosus Therapeutics Market 87

6 Rheumatology Therapeutics Market to 2018 - Pipeline Analysis 89
6.1 Pipeline Assessment by Clinical Phase of Development 89
6.2 Key R&D Trends and Future Outlook 90
6.3 Profiles of Promising Molecules 91
6.3.1 Tofacitinib 91
6.3.2 Fostamatinib 91
6.3.3 LY2127399 (tabalumab) 92
6.3.4 Naproxcinod 92
6.3.5 RDEA594 (lesinurad) 92
6.3.6 BCX4208 93
6.3.7 Epratuzumab 94
6.3.8 Lupuzor 94
6.3.9 Atacicept 94

7 Rheumatology Therapeutics Market to 2018 - Competitive Landscape 95
7.1 Abbott 95
7.1.1 Overview 95
7.1.2 Major Marketed Products 95
7.1.3 SWOT Analysis 96
7.2 Amgen 97
7.2.1 Overview 97
7.2.2 Major Marketed Products 97
7.2.3 SWOT Analysis 98
7.3 Pfizer 99
7.3.1 Overview 99
7.3.2 Major Marketed Products 99
7.3.3 SWOT Analysis 100
7.4 Janssen Biotech 101
7.4.1 Overview 101
7.4.2 Major Marketed Products 101
7.4.3 SWOT Analysis 102
7.5 Merck 103
7.5.1 Overview 103
7.5.2 Major Marketed Products 103
7.5.3 SWOT Analysis 104

8 Rheumatology Therapeutics Market to 2018 - Strategic Consolidations 105
8.1 Overview 105
8.1.1 Deals by Type of Agreement 106
8.1.2 Deals by Year 107
8.1.3 Deals by Geography 108
8.1.4 Profiling of Major Deals 109

9 Rheumatology Therapeutics Market - Appendix 113
9.1 Market Definitions 113
9.2 Abbreviations 113
9.3 Bibliography 113
9.4 Research Methodology 116
9.4.1 Coverage 116
9.4.2 Secondary Research 116
9.4.3 Primary Research 117
9.5 Therapeutic Landscape 117
9.5.1 Epidemiology-based Forecasting 118
9.5.2 Market Size by Geography 119
9.6 Geographical Landscape 120
9.7 Pipeline Analysis 120
9.8 Competitive Landscape 120
9.8.1 Expert Panel Validation 120
9.9 Contact Us 120
9.10 Disclaimer 120

List of Tables


Table 1: Rheumatology Therapeutics Market, Global, Revenue ($bn), 2005-2011 14
Table 2: Rheumatology Therapeutics Market, Global, Revenue Forecasts ($bn),  2011-2018 14
Table 3: Rheumatology Therapeutics Market, Global, Annual Cost of Therapy ($),  2005-2011 16
Table 4: Rheumatology Therapeutics Market, Global, Annual Cost of Therapy ($),  2011-2018 16
Table 5: Rheumatology Therapeutics Market, Global, Treatment Usage Patterns (million), 2005-2011 18
Table 6: Rheumatology Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018 18
Table 7: Rheumatology Therapeutics Market, The US, Revenue ($bn), 2005-2011 21
Table 8: Rheumatology Therapeutics Market, The US, Revenue Forecasts ($bn),  2011-2018 21
Table 9: Rheumatology Therapeutics Market, The US, Annual Cost of Therapy ($),  2005-2011 22
Table 10: Rheumatology Therapeutics Market, The US, Annual Cost of Therapy ($),  2011-2018 22
Table 11: Rheumatology Therapeutics Market, The US, Treatment Usage Patterns (million), 2005-2011 24
Table 12: Rheumatology Therapeutics Market, The US, Treatment Usage Patterns (million), 2011-2018 24
Table 13: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2005-2011 26
Table 14: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018 26
Table 15: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2005-2011 27
Table 16: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2011-2018 28
Table 17: Rheumatology Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2005-2011 29
Table 18: Rheumatology Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2011-2018 29
Table 19: Rheumatology Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2005-2011 30
Table 20: Rheumatology Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2011-2018 30
Table 21: Rheumatology Therapeutics Market, Japan, Revenue ($bn), 2005-2011 32
Table 22: Rheumatology Therapeutics Market, Japan, Revenue Forecasts ($bn), 2011-2018 33
Table 23: Rheumatology Therapeutics Market, Japan, Annual Cost of Therapy ($),  2005-2011 35
Table 24: Rheumatology Therapeutics Market, Japan, Annual Cost of Therapy ($),  2011-2018 35
Table 25: Rheumatology Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2005-2011 36
Table 26: Rheumatology Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2011-2018 36
Table 27: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2005-2011 47
Table 28: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 47
Table 29: Rheumatoid Arthritis Therapeutics Market, Global, Revenue by Country ($m), 2005-2011 48
Table 30: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018 49
Table 31: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2011 50
Table 32: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 50
Table 33: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Pattern (million), 2005-2011 51
Table 34: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Pattern (million), 2011-2018 51
Table 35: Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2005-2011 57
Table 36: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn),  2011-2018 57
Table 37: Osteoarthritis Therapeutics Market, Global, Revenue ($m), 2005-2011 59
Table 38: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 60
Table 39: Osteoarthritis Therapeutics Market, Global, Annual Cost of Therapy ($),  2005-2011 61
Table 40: Osteoarthritis Therapeutics Market, Global, Annual Cost of Therapy ($),  2011-2018 61
Table 41: Osteoarthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2005-2011 63
Table 42: Osteoarthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2011-2018 63
Table 43: Gout Therapeutics Market, Global, Revenue ($m), 2005-2011 68
Table 44: Gout Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 68
Table 45: Gout Therapeutics Market, Global, Revenue by Country ($m), 2005-2011 70
Table 46: Gout Therapeutics Market, Global, Revenue Forecasts by Country ($m),  2011-2018 71
Table 47: Gout Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2011 72
Table 48: Gout Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 72
Table 49: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions),  2005-2011 73
Table 50: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions),  2011-2018 73
Table 51: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue ($m), 2005-2011 80
Table 52: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 80
Table 53: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue by Country ($m), 2005-2011 81
Table 54: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018 82
Table 55: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2011 83
Table 56: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 83
Table 57: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2005-2011 85
Table 58: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2011-2018 85
Table 59: Rheumatology Therapeutics Market, Global, Deals by Type of Agreement (%), 2007-2012 106
Table 60: Rheumatology Therapeutics Market, Global, Deals by Geography (%), 2007-2012 108

List of Figures


Figure 1: Rheumatology Therapeutics Market, Global, Revenue Forecasts ($bn),  2005-2018 14
Figure 2: Rheumatology Therapeutics Market, Global, Annual Cost of Therapy ($),  2005-2018 16
Figure 3: Rheumatology Therapeutics Market, Global, Treatment Usage Patterns (million), 2005-2018 18
Figure 4: Rheumatology Therapeutics Market, The US, Revenue Forecasts ($bn),  2005-2018 21
Figure 5: Rheumatology Therapeutics Market, The US, Annual Cost of Therapy ($), 2005-2018 22
Figure 6: Rheumatology Therapeutics Market, The US, Treatment Usage Patterns (million), 2005-2018 24
Figure 7: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2005-2018 26
Figure 8: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2005-2018 27
Figure 9: Rheumatology Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2005-2018 29
Figure 10: Rheumatology Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2005-2018 30
Figure 11: Rheumatology Therapeutics Market, Japan, Revenue Forecasts ($bn),  2005-2018 32
Figure 12: Rheumatology Therapeutics Market, Japan, Annual Cost of Therapy ($), 2005-2018 34
Figure 13: Rheumatology Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2005-2018 36
Figure 14: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2005-2018 47
Figure 15: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2005-2018 48
Figure 16: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2018 50
Figure 17: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Pattern (million), 2005-2018 51
Figure 18: Rheumatoid Arthritis Therapeutics Market, Rheumatoid Arthritis, Treatment Flow Algorithm 53
Figure 19: Rheumatoid Arthritis Therapeutics Market, Drivers and Barriers 53
Figure 20: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn),  2005-2018 57
Figure 21: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($m),  2005-2018 59
Figure 22: Osteoarthritis Therapeutics Market, Global, Annual Cost of Therapy ($),  2005-2018 61
Figure 23: Osteoarthritis Therapeutics Market, Global, Osteoarthritis Pain Treatment Algorithm 62
Figure 24: Osteoarthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2005-2018 63
Figure 25: Osteoarthritis Therapeutics Market, Global, Drivers and Barriers 65
Figure 26: Gout Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2018 68
Figure 27: Gout Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2005-2018 70
Figure 28: Gout Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2018 72
Figure 29: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions),  2005-2018 73
Figure 30:  Gout Therapeutics Market, Treatment Flow Algorithm for Gout 75
Figure 31: Gout Therapeutics Market, Global, Drivers and Barriers 75
Figure 32: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2018 79
Figure 33: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2005-2018 81
Figure 34: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2018 83
Figure 35: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2005-2018 85
Figure 36: Systemic Lupus Erythematosus Therapeutics Market, Treatment Flow Algorithm 87
Figure 37: Systemic Lupus Erythematosus Therapeutics Market, Global, Drivers and Barriers 87
Figure 38: Rheumatology Therapeutics Market, Global, Pipeline Molecules by Stage of Development, May, 2012 89
Figure 39: Rheumatology Therapeutics Market, Abbott, SWOT Analysis 96
Figure 40: Rheumatology Therapeutics Market, Amgen, SWOT Analysis 98
Figure 41: Rheumatology Therapeutics Market, Pfizer, SWOT Analysis 100
Figure 42: Rheumatology Therapeutics Market, Janssen Biotech, SWOT Analysis 102
Figure 43: Rheumatology Therapeutics Market, Merck, SWOT Analysis 104
Figure 44: Rheumatology Therapeutics Market, Global, Deals by Type of Agreement (%), 2007-2012 106
Figure 45: Rheumatology Therapeutics Market, Global, Deals by Year, 2007-2012 107
Figure 46: Rheumatology Therapeutics Market, Global, Deals by Geography (%),  2007-2012 108
Figure 47: GBI Research Market Forecasting Model 119

Upcoming Reports:

Palm Oil Market - Global Industry Analysis, Size, Market Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Palm oil is one of the most commonly consumed edible oils and is extracted from the fruit of the palm tree. It has comparatively low cost and does not have any trans fat, making it ideal for use in the food industry. India, Indonesia, and China are the major consumers of palm oil in the world and with the growth in emerging economies, the demand for this oil is expected to grow. Palm oil based on type is segregated into palm oil, palm kernel oil and others. It is used in applications like food, health, energy and others, which includes cosmetics. One of the focuses of the...
Motion Sensors Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
With constant innovation in sensors technology, there has been an increase in the use of motion sensors in various applications thus providing a boost to the overall motion sensors market. This market is expected to grow exponentially in the next few years at a double digit compounded annual growth rate. This research report analyzes the sensor market on the basis of its segments and major geographies. The report is a complete study that provides detailed information about trend analysis, market numbers, industry growth drivers, and restraints along with future market projections....
Autacoids and Related Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
Autacoids are certain biological factors that act like hormones and help in treating local injuries and other ailments. Autacoids are temporarily formed in the body and act locally. They have many different actions such as modulation of action of glands, smooth muscles, platelets, nerves, and other tissues. They are released by stimuli and when they are released into the body, they can bring certain changes such as itching, skin reddening, and bronchospasms. Some of these changes are undesirable and for the prevention of such symptoms, autacoids antagonists are used. ...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

                    

Related News

One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012  
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012  
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012  
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
Battling against flu, vaccination necessary for health workers
Sep 14, 2012  
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012  
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...